Abstract:Abstract Background: While the genetic landscapes of pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are well described, the contribution of individual genes and transcriptomic programs to tumor initiation, progression and metastasis remain incompletely understood. To quantify the oncogenic potential of individual genes and identify transcriptomic programs that drive progression and metastasis, we have developed a platform for in vivo CRISPR activation (CRISPRa) screening that allows us to delineate tissue-specific oncogene selection. Material and Methods: Our platform consists of a conditional, CRISPRa-competent, murine tumor model (PPKS; P53(F/F), Kras(LSL-G12D/+), R26(LSL-SAM), coupled with targeted delivery of Cre-recombinase/sgRNA library encoding lentivirus [1]. We designed a CRISPRa screening library targeting 452 of the most commonly amplified and mutated genes across human adenocarcinoma. Using this library, we generated pancreatic and lung tumors, and harvested tissues and metastatic lesions at multiple time points (6 days, 4 weeks, 8 weeks, and endpoint). The change in guide distribution over time was then determined using NGS and bioinformatic analysis. To confirm the oncogenic potential of the most highly enriched genes, single gene-activated tumors were compared to non-targeted controls. Results: We found that essentially all guides (99.9%) were represented in vivo at the 6-day time point. The degree of guide selection increased over time and was significantly higher in the pancreas relative to the lung, indicating a higher degree of parallel tumor evolution in the lung. Lung samples were characterized by Egfr, Sox2 and Myc displaying gradually increasing enrichment over time and Egfr displayed the highest level of enrichment in endpoint lung tumors. In stark contrast, pancreas samples were almost completely dominated by Myc activation at the 4-week timepoint, with increased enrichment in the later timepoints, indicating a strong competitive advantage of Myc-activation, specifically in the pancreas. To confirm the pro-tumorigenic role of Myc in the pancreas, we analyzed the survival and phenotype of Myc-activated PPKS tumors, which revealed accelerated tumor progression relative to controls. Conclusions: We present one of the first implementations of autochthonous in vivo CRISPR activation screening, allowing for direct observation and quantification of oncogene selection and competition in vivo. Our results replicate tissue-specific differences in oncogene selection and indicate a dominant role of Myc-activation in pancreatic oncogenesis. Our platform has the potential to be used to address a wide range of inquiries into tumor biology, including drivers of progression, metastasis and resistance to targeted therapies. References: 1.Thege, F. I. et al. A programmable in vivo CRISPR activation model elucidates the oncogenic and immunosuppressive functions of MYC in lung adenocarcinoma. Cancer Res (2022) Citation Format: Fredrik I. Thege, Sonja M. Woermann, Anirban Maitra. Delineating tissue-specific oncogene selection with autochthonous CRISPR activation screening [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr C057.

Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice

In situ CRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer

Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice

Efficient and multiplexed somatic genome editing with Cas12a mice

A prime editor mouse to model a broad spectrum of somatic mutations in vivo

A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer

Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening

Abstract C057: Delineating tissue-specific oncogene selection with autochthonous CRISPR activation screening

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Abstract 2929: Multiplexed somatic genome editing to model and investigate advanced colorectal cancer

Precision Cancer Mouse Models Through Genome Editing with CRISPR-Cas9.

Abstract LB357: CRISPR-Cas9 targeting of somatic mutations selectively kills cancer cells

CRISPR-mediated Direct Mutation of Cancer Genes in the Mouse Liver.

A Novel CRISPR/Cas9-mediated Mouse Model of Colon Carcinogenesis

Abstract PR02: Modeling breast cancer through somatic precision gene editing with high flexibility and efficiency

Rapid interrogation of cancer cell of origin through CRISPR editing

Abstract 3: In vivo CRISPR activation screening identifies tissue-specific oncogene selection

A CRISPR-Cas13a System for Efficient and Specific Therapeutic Targeting of Mutant KRAS for Pancreatic Cancer Treatment.

Abstract 2194: Rapid interrogation of colon cancer driver genes in vivo using split Cre and CRISPR-Cas9

High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics

Abstract C034: Genome-wide CRISPR screen identifies novel immunotherapeutic targets in pancreatic cancer